The aberrant gain of DNA methylation at CpG islands (CGIs) is frequently observed in colorectal tumours and may silence the expression of tumour suppressors such as MLH1. Current models propose that these CGIs are targeted by de novo DNA methyltransferases (DNMTs) in a sequence-specific manner but this has not been tested. Using ectopically integrated CGIs, we find that aberrantly methylated CGIs are subject to low levels of de novo DNMT activity in colorectal cancer cells. By delineating DNMT targets, we find that instead de novo DNMT activity is targeted primarily to CGIs marked by the histone modification H3K36me3, a mark associated with transcriptional elongation. These H3K36me3 marked CGIs are heavily methylated in colorectal tumours and the normal colon suggesting that de novo DNMT activity at CGIs in colorectal cancer is focused on similar targets to normal tissues and not greatly remodelled by tumourigenesis.
Introduction
DNA methylation is an epigenetic mark associated with gene repression. It is normally pervasive in mammalian genomes but absent from many regulatory elements, particularly CGIs 1 . In tumours, CGIs often become aberrantly methylated.
In some cases hypermethylated CGIs correspond to the promoters of tumour suppressor genes such as MLH1, CDKN2A (p16/ARF) and BRCA1 2 . At these genes, hypermethylation associates with repression and thus could drive tumourigenesis. In support of this hypothesis, targeted methylation of the CDKN2A promoter in mammary epithelial cells prevents their entry into senescence 3 . However, aberrant CGI hypermethylation also occurs at many other CGIs that are not obviously the promoters of tumour suppressor genes 2 . These aberrantly methylated CGIs are often repressed by Polycomb Repressive Complexes and marked by H3K27me3 in the normal cells that give rise to the cancer 4-6 . However, the mechanisms underpinning the aberrant hypermethylation of CGIs in cancer remain unclear.
DNA methylation is established and maintained in human cells by DNMT1, DNMT3A and DNMT3B 7 . DNMT3A and DNMT3B are de novo methyltransferases that establish methylation patterns during early development 8 . DNMT1 is the main enzyme responsible for maintaining DNA methylation 9 . It has a preference for acting at hemimethylated sites in vitro 10 and also interacts with PCNA at replication forks 11 . DNMT3B is the methyltransferase most often implicated in the aberrant methylation of CGIs in cancer. DNMT3B levels are often increased in cancers relative to normal tissues and higher levels in colorectal tumours correlate with the aberrant methylation of several CGIs 12, 13 . Aberrant methylation at CGIs in cancer could be programmed by the sequence-specific recruitment of DNMTs through transcription factors 14 . The transcription factor MAFG is proposed to directly recruit DNMT3B to CGIs methylated in BRAF mutant colorectal tumours 15 . A parallel study suggested that in KRAS mutant colorectal cancer, DNMT1 is recruited by ZNF304 to cause de novo methylation of several genes including CDKN2A 16 . However, in mouse embryonic stem (ES) cells, DNMT3B is targeted to regions marked by H3K36me3 17 .
These observations suggest a model in which DNMT activity in cancer cells is remodelled to target H3K27me3 marked CGIs in a sequence-specific manner resulting in their aberrant methylation. Despite this, previous studies have not measured de novo DNMT activity at CGIs in cancer cells and it is unclear whether it is indeed elevated at those that are aberrantly methylated.
Here we use different experimental strategies to assay de novo DNMT activity at CGIs in colorectal cancer cells. In contrast to current models, we find that the highest levels of de novo DNMT activity are found at CGIs that are marked by H3K36me3 and methylated in the normal colon.
Results

CGIs are not de novo methylated at ectopic locations in colorectal cancer cells
The ectopic integration of CGIs has been used to demonstrate strong sequencespecific programming of CGI DNA methylation levels by transcription factors in mouse ES cells 18 . Therefore, in order to understand whether de novo DNMTs are targeted to CGIs that are aberrantly methylated in colorectal cancer in a sequencespecific manner we asked whether these CGIs become methylated when integrated into ectopic locations in the genome of colorectal cancer cells. If DNMTs were specifically recruited to these CGIs in a sequence-specific manner, the initially unmethylated ectopic integrants would be expected to rapidly acquire high levels of DNA methylation.
We used piggyBac transposons to randomly integrate copies of 10 CGIs into the genome of HCT116 cells (Fig. 1A) . We tested 6 aberrantly methylated CGIs that are methylated in HCT116 cells (CDKN2A, SFRP1, ZFP42, GATA4, CDH7 and CDH13), a housekeeping CGI promoter that does not become hypermethylated in colorectal cancer, BUB1, and a normally methylated CGI, DAZL. The CGI promoter of the tumour suppressor gene MLH1 that is unmethylated in HCT116 cells was also tested.
Cells populations carrying CGI integrations were then expanded for 4 weeks to ensure free plasmid was no longer present in the population before we determined DNA methylation levels at the integrated copies and native locus using specific bisulfite PCR primers. Each ectopically integrated copy assayed will derive from a separate integration site in the population of transfected cells thus sampling a diverse array of different genomic locations.
The BUB1 and MLH1 CGIs both remained unmethylated when integrated into ectopic locations using piggyBac (Fig. 1B) . The vast majority of integrated copies of the aberrantly methylated CGIs tested also did not become de novo methylated ( Fig.   1B ,C). Rare cases of methylation observed at integrated copies were low level and heterogeneous ( Fig. 1C ) but confirmed that HCT116 cells are capable of de novo methylation as previously reported 19 . The highest levels of methylation observed were at ectopic copies of the CDH13 CGI but these were still much lower than those seen at the native locus ( Fig. 1B) . Ectopic copies of the DAZL CGI also did not become methylated to a high level ( Fig. 1B) suggesting that it is only targeted by de novo DNMTs when it gains methylation early in development 20 .
Overall, the results of this experiment suggest that in HCT116 cells surprisingly low de novo DNMT activity is targeted in a sequence-specific manner to those CGIs that frequently become hypermethylated in colorectal cancer.
DNMT3B targets H3K36me3 marked CGIs in colorectal cancer cells
Given that our experiments with ectopically integrated CGIs suggested that aberrantly methylated CGIs were not strongly targeted by de novo DNMT activity, we next sought to determine which CGIs were targeted by DNMTs in colorectal cancer. We focused on DNMT3B because of its prior associations with aberrant methylation of CGIs in colorectal cancer 12, 13 . We therefore reintroduced DNMT3B2, the major catalytically active DNMT3B isoform expressed in somatic cells (henceforth referred to as DNMT3B) 21 , into hypomethylated HCT116 cells which lack DNMT3B and express low levels of a truncated DNMT1 product (DKO cells) 22,23 .
Regions of the genome targeted by DNMT3B will gain methylation in this experiment. DNMT3B expression in DKO cells led to increased total methylation levels, as measured by mass-spectrometry, from 60.6% to 81.1% of the level observed in HCT116 cells (gain of 20.5%, Supplementary Fig. 1A ). A gain of 9.04% was also observed when catalytically dead DNMT3B was reintroduced ( Supplementary Fig. 1A ).
We then used reduced representation bisulfite sequencing (RRBS) 24 to determine which CGIs gained methylation in DKO cells upon reintroduction of DNMT3B. In this experiment 2,238 CGIs gained significant levels of methylation and are putative DNMT3B targets ( Fig. 2A , ≥20% methylation gain and Benjamini-Hochberg corrected Fisher's exact tests p < 0.05). When cross-referenced to HCT116 histone modification ChIP-seq data from ENCODE 25 , these CGIs were significantly enriched in regions marked by H3K36me3 ( Fig. 2B , C). To directly examine the relationship between H3K36me3 and gain of methylation upon DNMT3B expression, we ranked CGIs by their H3K36me3 level in HCT116 cells. Those CGIs with the highest levels of H3K36me3 in HCT116 cells gained the most DNA methylation in DKO when DNMT3B is reintroduced ( Fig. 2D ).
We then conducted a second experiment, expressing DNMT3B to a higher level (using the CAG promoter rather than EF-1α, Supplementary Fig. 1B ). This resulted in a greater gain of methylation at H3K36me3 marked CGIs and more CGIs were restored to the levels observed in HCT116 cells ( Supplementary Fig. 1C , D). Ectopic gains of methylation at loci hypomethylated in HCT116 cells were also observed in this 2 nd experiment ( Supplementary Fig. 1C , arrow). Catalytically dead DNMT3B also caused a significant gain in DNA methylation at H3K36me3 marked CGIs compared to a GFP expressing control although this was to a lower level than that seen with catalytically active DNMT3B ( Supplementary Fig. 1C, D) . The level of methylation gain seen with catalytically dead DNMT3B was similar in both the low and high expression experiments ( Supplementary Fig. 1D ). DNMT3A and DNMT3B are known to interact 26 . Interactions between catalytically dead DNMT3B and DNMT3A could therefore be responsible for these gains as DNMT3A is upregulated in DKO cells compared to HCT116 cells ( Supplementary Fig. 1E ).
To confirm that DNMT3B normally targets CGIs gaining methylation in our DKO experiments, we used CRISPR to introduce an N-terminal T7 tag on DNMT3B in HCT116 cells (T7-DNMT3B cells) and performed ChIP-qPCR. N-terminal tagged DNMT3B is catalytically active in vivo 27 and we observed no loss of methylation at representative CGIs in T7-DNMT3B cells ( Supplementary Fig. 1F ). DNMT3B was significantly enriched at gene body CGIs in the VWA1 and TNFRSF1A genes that are methylated in HCT116 and gained methylation when DNMT3B was expressed in DKO cells ( Fig. 2E ). No enrichment of DNMT3B was seen at the BRCA2 promoter CGI, a housekeeping gene that does not gain methylation in DKO cells expressing DNMT3B ( Fig. 2E ). Taken together, our experiments in DKO cells and T7-DNMT3B cells suggest that DNMT3B is primarily targeted to CGIs that are marked by H3K36me3 in colorectal cancer.
H3K36me3 marked CGIs preferentially recover methylation following pharmacological hypomethylation
To quantify de novo DNMT activity at CGIs without ectopically overexpressing or focusing on specific DNMTs, we hypomethylated HCT116 cells using the demethylating drug 5-aza-2'-deoxycytidine (5-aza-dC) before measuring their recovery of DNA methylation. At 3 days following 5-aza-dC treatment, total DNA methylation had decreased to 49.9% of that in untreated cells (Supplementary Fig.   2A ). HCT116 cells recovered methylation to levels similar to untreated cells within 22 days after 5-aza-dC treatment (Supplementary Fig. 2A ). In order to compare the relative recovery rate of different CGIs, we performed RRBS across this time-course ( Fig. 3A) . The re-methylation observed in this experiment could be the result of de novo DNMT activity or the outgrowth of cells that escaped 5-aza-dC induced hypomethylation. However, we observed significant heterogeneity in the normalised recovery rates for different CGIs (p=1.31x10 -25 by ANOVA, see materials and methods) suggesting that the recovery of methylation was not solely explained by the outgrowth of cells escaping 5-aza-dC induced hypomethylation.
H3K36me3 marked CGIs lost significantly more methylation than other HCT116 methylated CGIs at 3 and 6 days following 5-aza-dC treatment ( Fig. 3B ). However, we observed that H3K36me3 marked CGIs recovered DNA methylation significantly more rapidly than other CGIs at later time-points ( Fig. 3B ). Quantification of the individual normalised rates of methylation gain for each CGI confirmed that remethylation was significantly faster at H3K36me3 marked CGIs than other CGIs ( Supplementary Fig. 2C ). This is consistent with the difference in remethylation kinetics observed in HCT116 cells being caused by differential de novo DNMT activity and suggests that H3K36me3 marked CGIs are preferential targets of de novo DNMT activity in colorectal cancer cells.
H3K36me3 marked CGIs are methylated in colorectal tumours and the normal colon
Given that our experimental data suggested that de novo DNMT activity in colorectal cancer cells is primarily targeted to CGIs marked by H3K36me3, we wanted to understand whether H3K36me3 patterns were remodelled in colorectal cancer to cause aberrant hypermethylation at some CGIs.
We defined colorectal tumour H3K36me3 marked CGIs by re-analysing H3K36me3
ChIP-seq data from a colorectal tumour 28 . Using TCGA Infinium methylation array data from 342 colorectal tumours and 42 normal colon samples 29 we found that the vast majority of H3K36me3 CGI probes were highly methylated in clinical specimens ( Fig. 4A-C) . In contrast, CGI probes associated with H3K4me3, a mark that repels DNMT3 enzymes 30 , had significantly lower methylation levels in clinical colorectal tumours ( Fig. 4B-C ).
Our analysis also demonstrated that H3K36me3 marked CGIs were highly methylated in the normal colon samples ( Fig. 4A-C ). An analysis of 38 matched tumour-normal pairs from TCGA confirmed that these CGIs had similar methylation levels in the normal colon and colorectal tumours (mean Pearson correlation=0.826).
The correlation between matched samples for H3K4me3 peaks was significantly lower (mean 0.694, p=2.90x10 -9 , Wilcoxon rank sum test). Using data from the Roadmap Epigenomics project, we then asked if colorectal tumour H3K36me3 marked CGIs were also associated with H3K36me3 in the normal colon. Our analysis showed strong normal colon H3K36me3 signal at these CGIs and 758/1061 overlapped a normal colon H3K36me3 peak (71.4%, p < 2.2x10 -16 , Fishers exact test, Taken together, these analyses suggest that the CGIs that are marked by H3K36me3, which are subject to high de novo DNMT in colorectal cancer cells, are highly methylated in both clinical colorectal tumours and the corresponding normal tissue and that H3K36me3 patterns are not extensively remodelled at CGIs in colorectal tumours.
Discussion
Here we present the first comprehensive assessment of de novo DNMT activity at CGIs in colorectal cancer. Our results suggest that this is primarily directed towards gene body CGIs marked by H3K36me3, a histone modification associated with ongoing active transcription, and lower levels are targeted to aberrantly methylated CGIs ( Fig. 5 ). We find that these CGIs are not only highly methylated in tumours but also the normal colon suggesting that de novo DNMTs target similar CGIs in both normal somatic tissues and cancers.
Our observation that the highest levels of de novo methylation at CGIs in cancer cells are targeted towards those associated with H3K36me3 parallels observations made in diverse systems. Both DNMT3A and DNMT3B possess a PWWP domain that binds H3K36me3 31 . In mouse embryonic stem cells DNMT3B is primarily localised to H3K36me3 17 and DNMT3B knockout leads to preferential loss of DNA methylation from H3K36me3 marked regions 32 . H3K36me3 is deposited by SETD2 through its association with RNA polymerase II 33 . Transcription induced deposition of H3K36me3 leads to DNMT3B-dependent methylation of CGIs in mouse ES cells 34 and is associated with de novo methylation of imprinting control regions in mouse oocytes 35 . Previous work in DKO cells suggests DNMT3B is targeted to H3K36me3 in gene bodies but did not examine CGIs 36 .
Here we have focused on assays that detect de novo methylation irrespective of the enzyme involved. Overall, they suggest that de novo DNMT activity is primarily targeted to H3K36me3 marked CGIs irrespective of the DNMT responsible but support a model in which the bulk of the de novo DNMT activity at H3K36me3 marked CGIs is dependent of DNMT3B. We also observe gains of DNA methylation at H3K36me3 marked loci when catalytically inactive DNMT3B is introduced into DKO cells. This correlates with increased DNMT3A levels in DKO cells. DNMT3A and B can interact 26 and a previous study suggested that catalytically inactive DNMT3B may recruit DNMT3A to H3K36me3 marked gene bodies 36 . Part of the de novo DNMT activity we measure at H3K36me3 marked CGIs in colorectal cancer cells could therefore be mediated by DNMT3A rather than DNMT3B but is dependent on DNMT3B for recruitment.
Current models suggest that DNMTs are targeted to aberrantly methylated CGIs in colorectal cancer by transcription factors 15, 16 . Aberrantly methylated CGIs are generally repressed in normal cells and associated with H3K27me3 and Polycomb Repressive Complexes rather than H3K36me3 4-6 . Our results in this study suggest that the sequences of aberrantly methylated CGIs inefficiently recruit de novo DNMTs and are inconsistent with models of de novo methylation based on recruitment by transcription factors. A similar assay has previously been used to demonstrate sequence-specific programming of DNA methylation at CGIs by transcription factors in mouse ES cells 18 . Our observations suggest that aberrant CGI hypermethylation could occur through an inefficient, slow process associated with low de novo DNMT activity. In support of this hypothesis, the aberrantly methylated GSTP1 CGI promoter acquires little methylation when it is ectopically introduced into prostate cancer cells but gains of methylation were stimulated by prior in vitro seeding of low-level DNA methylation 37 .
Here we have used an established cancer cell line that does not model early stages of transformation. It is possible that a wave of de novo DNMT activity is targeted to aberrantly methylated CGIs specifically at the point of transformation paralleling the wave of genome-wide de novo methylation observed during early development 38 . If the signals causing this wave of de novo DNMT activity were subsequently lost in advanced tumours, they would not be ascertained in experiments using established cancer cell lines. However, oncogenic mutations are proposed to be the signal responsible for instructing de novo methylation 15, 16 and these persist in advanced cancers and cell lines. HCT116 cells also have the ability to de novo methylate retroviral DNA sequences 19 and we observe some de novo methylation at ectopic CGIs.
H3K36me3 has not been extensively examined in colorectal cancer, but gains of DNA methylation in cancer have previously been associated with transcription across CGIs. In colorectal and breast tumours the TFPI2 promoter is aberrantly hypermethylated in association with transcription originating from a nearby LINE-1 promoter 39 . Also Lynch syndrome can be caused by the constitutive hypermethylation of the tumour suppressor MSH2 associated with read-through transcription from the upstream gene caused by a genetic deletion 40 . Given the association of SETD2 with RNA polymerase II 33 , these cases of transcriptionassociated hypermethylation would be expected to be associated with H3K36me3 deposition as observed in experiments examining the effect of transcription across CGIs in differentiating mouse ES cells 34 . We find that colorectal tumour H3K36me3 marked CGIs are also associated with H3K36me3 and high levels of DNA methylation in the normal colon. This suggests that H3K36me3 patterns are not extensively remodelled in colorectal tumours compared to normal tissue and that transcriptioncoupled deposition of H3K36me3 is an infrequent cause of aberrant CGI hypermethylation in colorectal tumours. Instead the recruitment of high de novo DNMT activity to H3K36me3-marked gene body CGIs might serve to prevent spurious transcription from these potential promoter sequences interfering with the expression of the associated genes 1, 32 .
Taken together our study suggests that the targeting of de novo DNMT activity to CGIs in colorectal cancer is similar to that in normal cells and is predominantly centred on CGIs marked by H3K36me3.
Methods
Cell culture
HCT116, DNMT1 KO, DNMT3B KO, and DKO cells were gifts from B. Vogelstein 22,23 .
Cells were cultured in McCoy's 5A medium (Gibco) supplemented with 10% fetal calf serum (Life technologies) and penicillin-streptomycin antibiotics at 140 and 400 µg/ml respectively.
Generation of plasmid constructs
To create piggyBac transposon constructs containing CGIs, we amplified the CGIs from HCT116 cell genomic DNA and cloned them into the pEGFP-N2-pB-min containing piggyBac terminal repeats. To generate the plasmid pEGFP-N2-pB-min we removed the multiple cloning site (MCS) of the pEGFP-N2 plasmid (Clontech) by BamHI-NheI double digestion, Klenow-mediated blunt ending and ligation. We then added a new MCS flanked by the minimal terminal repeats sufficient for PiggyBac transposition 41, 42 . The new MCS was generated from two commercially synthesized oligonucleotides (IDT, oligo sequences in Supplementary Table 2 ) and inserted into the vector by In-Fusion cloning (TakaraBio). CGI sequences were amplified using specific primers with 15bp overhangs (Supplementary Table 2 for primer sequences) to facilitate In-Fusion cloning into pEGFP-N2-pB-min following the manufacturer's instructions.
To create the piggyBac DNMT3B expression vector, the DNMT3B2 sequence from pcDNA3/Myc-DNMT3B2 plasmid (Addgene plasmid 36942, a gift from A. Riggs) 27 was subcloned using XbaI and BamHI into the pCG plasmid (a gift from N. Gilbert) downstream of the T7 tag. The catalytically inactive point mutation C265S 43 was introduced using the QuikChange II site-directed mutagenesis kit (Agilent) to create T7-DNMT3B2 catalytic dead (CD). T7-DNMT3B2 and T7-DNMT3B2-CD were then cloned into pB530A-puroVal2 using BamHI and EcoRI (weak-expression vector with EF-1α promoter), and in PB-CGIP by swapping eGFP using AgeI and NotI (strong expression vector with CAG promoter, a gift from M. McCrew) 44 . pB530A-puroVal2 was previously created by substituting the copepod GFP from the pB530A plasmid (System Biosciences) with a Puromycin resistance gene.
Ectopic integration of CGIs
HCT116 cells were transfected using FuGENE HD transfection reagent (Promega). To ectopically integrate CGIs, mCherry expressing piggyBac transposase (gift from W. Akhtar) 45 was co-transfected with piggyBac CGI transposons into HCT116 cells in 1:1 ratio. After 48 hrs, cells expressing both GFP and mCherry were selected by FACS and expanded for 4 weeks to dilute out free plasmid. DNA was purified with phenolchloroform extraction and ethanol precipitation. The methylation levels of CGIs at native and ectopic locations were then assessed by bisulfite PCR (primers listed in Supplementary Table 2 ). Supplementary Table 2 . Individual positive bacterial colonies were Sanger sequenced using SP6 or T7 sequencing primers (Supplementary Table 2 ) and analyzed using BIQ Analyzer software (for piggyBAC CGI experiment) 46 or BISMA (for T7-DNMT3B cell line) 47 . To generate figures, results were then extracted from the BIQ or BISMA output HTML files using custom R scripts. Clones with ≥25% sequencing errors were excluded from analyses.
DNMT3B expression in DKO cells
5-aza-2'-deoxycytidine time-course
Cells were plated at ~20% confluency. Next day cells were treated with freshly prepared 1µM 5-aza-dC (Sigma Aldrich) for 24 hrs. Cell pellets were collected at different time points following treatment and genomic DNA was extracted using DNeasy Blood & Tissue Kit (QIAGEN) following the manufacturer's instructions.
Western blotting
Whole-cell extracts were obtained by sonication in UTB buffer (8 M urea, 50 mM Tris, pH 7.5, 150 mM β-mercaptoethanol) and quantified using A 280 from a NanoDrop This is predicted to cause a frameshift with a severely truncated product on the second allele or be subject to nonsense mediated decay. Primers and oligonucleotides used are listed in Supplementary Table 2 . 
Generation of CRISPR/Cas9-edited HCT116 cell line
Chromatin immunoprecipitation and qPCR
Global measurement of DNA methylation by mass-spectrometry
1μg genomic DNA was denatured at 95°C for 10 min in 17.5μL water. DNA was then digested to nucleotides overnight at 37°C with T7 DNA polymerase (Thermo Scientific). The reaction was inactivated by incubating at 75°C for 10 min. Samples were then centrifuged for 45min at > 12,000g and the supernatant transferred into new tubes for analysis. Enzyme was removed by solvent precipitation. The samples were adjusted back to initial aqueous condition and volume and LC-MS was performed on a Dionex Ultimate 3000 BioRS / Thermo Q Exactive system, using a Hypercarb 3 µm x 1 mm x 30 mm Column (Thermo 35003-031030) and gradient from 20 mM ammonium carbonate to 2 mM ammonium carbonate 90% acetonitrile in 5 minutes. Data were acquired in negative mode, scanning at 70k resolution from 300 to 350 m/z. Extracted ion chromatograms were analysed using Xcalibur (Thermo Scientific) to extract peak intensities at the m/z values expected for each nucleotide (based on annotation from METLIN) 49 following manual inspection to ensure that they were resolved as clear single peaks. The % of 5-methylcytosine present in the sample was calculated as the ratio of the area under the 5-methylcytosine peak to the area under the guanine peak.
Statistical analysis
Statistical testing was performed using R v3.4.2. All tests were two-sided, unless otherwise stated. Further details of specific analyses provided in the relevant methods sections below.
CGI definition
CGI annotation was taken from Illingworth et al. 50 . Overlapping CGI intervals were merged using BEDtools (version 2.27.1) 51 before they were converted to hg38 positions using the UCSC browser liftover tool. Non-autosomal CGIs were excluded from the analysis as were CGIs located in ENCODE blacklist regions 25 . Processed RRBS files were assessed for conversion efficiency based on the proportion of methylated reads mapping to the λ genome spike-in (>99.5% in all cases). For summary of RRBS alignment statistics see Supplementary Table 3 .
RRBS data generation and processing
BigWigs were generated from RRBS data using CpGs with coverage ≥5.
Analysis of RRBS data
CGI methylation levels were calculated as the weighted mean methylation using the observed coverage of CpGs within the CGI (unconverted coverage/total coverage).
Only CpGs with a total coverage ≥ 10 in all samples were considered in each analysis.
Methylated CGIs were defined as those where the weighted-mean % methylation was ≥ 70%. CGIs significantly gaining methylation upon expression of DNMT3B in DKO cells were defined as those with a Benjamini Hochberg adjusted Fisher's exact test p-value < 0.05 and where ≥ 20% methylation was gained. To analyse histone marks at these CGIs, the number overlapping HCT116 ChIP-seq peaks was compared to the number overlapping all CGIs in the analysis using Fisher's exact tests.
Analysis of re-methylation kinetics following 5-aza-2'-deoxycytidine treatment
If re-methylation following 5-aza-dC treatment was entirely driven by outgrowth of unaffected cells, we expect the methylation trajectory of each CGI to be proportional to its initial methylation level ( Supplementary Fig. 3) . In order to test this possibility, we normalised HCT116 methylation data for all CGIs with day 0 mean CGI methylation > 50% over the methylation value at day 0. Two models were fitted to this normalised data using time-points between day 3 and day 22 inclusive. The null hypothesis that re-methylation is due to outgrowth was represented by the mixed linear model shown in equation 1. The hypothesis that each CGI is remethylated at a different rate was represented by a mixed linear model accounting for a different trajectory for each CGI shown in equation 2.
Where is mean normalised methylation, is time, !"# is the random intercept for each CGI, and !"# is the random slope for each CGI. Comparing the models with ANOVA reveals that the probability that the null hypothesis is a better fit to the data is p=1.31x10 -25 , strongly suggesting that the CGIs do not recover methylation at the same rate. The R function lmer from the lme4 package (v1.1) was used for this analysis.
In order to investigate the trajectories of each CGI independently from one another, a linear model was fitted to the normalised methylation of each individual CGI at time points between day 3 and day 22 inclusive. The slopes of these individual linear models are equal to the fraction of methylation recovered per day. This analysis was repeated for the DNMT3B KO and DNMT1 KO cell lines.
Processing of ChIP-seq data
Processed ChIP-seq data from the normal colon and HCT116 cells were downloaded from ENCODE 25 as aligned BAM files and replicated peak BED files. The corresponding annotated input control was also downloaded for each sample. Multi-mapping reads excluded using SAMtools (v1.6, with settings: -bq 10) 54 and PCR duplicates excluded using SAMBAMBA (v0.5.9) 55 .
Tracks for data visualisation were generated using Homer (v4.8) 56 . Aligned BAMs were converted to tag directories setting the fragment length to 180bp and converted to bigWig files using Homer's makeUCSCfile function after filtering with the removeOutOfBounds.pl function. ChIP-seq peaks were called from tag directories using Homer's findPeaks function (settings: -style histone) and an input chromatin control sample.
Analysis of ChIP-seq pileups
Non-overlapping windows of 250bp were defined centred on the midpoint of each CGI, with ChIP-seq read counts/window calculated using BEDtools' coverage function. Read counts were scaled to counts per 10 million based on total number of mapped reads/sample and divided by the input read count to provide a normalised read count. To prevent windows with zero reads in the input sample generating a normalised count of infinity, an offset of 0.5 was added to all windows prior to scaling and input normalisation. Regions where coverage was 0 in all samples were removed from the analysis. Colour scales for ChIP-seq heatmaps range from the minimum to the 90% quantile of the normalised read count. ChIP-seq peaks were overlapped with CGIs using BEDtools intersect and tested for statistical enrichment with Fisher's exact tests versus all CGIs included in each analysis. To statistically test differences in histone modification levels, normalised read depths across CGIs were compared using a Wilcoxon rank sum test.
Infinium array data processing
All available colorectal tumour and normal colon data were downloaded from TCGA Genomic Data Commons as raw IDAT files on 13/9/18 29 . These were processed using the ssNoob approach from the Bioconductor package minfi (v1.22.1) to derive beta values and detection p-values (beta threshold = 0.001) 57,58 . Individual beta values were excluded where detection p-value was > 0.01. Non-CG probes were also excluded from the analysis. Samples that did not represent primary tumour or adjacent normal colon tissue were excluded using TCGA sample type codes as were samples where ≥ 1% of probes failed the detection p-value threshold. Where replicates existed for these tumour and normal samples, the mean was calculated Wilcoxon rank sum test.
Figure 5
De novo DNA methyltransferase activity in colorectal cancer is directed towards
H3K36me3 marked CpG islands
Graphical model of the distribution of de novo DNMT activity at CGIs in colorectal cancer. Our data support a model whereby the CGIs subject to the highest levels of de novo DNMT activity in both the normal and cancerous colon are those marked by
H3K36me3. Although CGIs marked by H3K27me3 in the normal colon become aberrantly methylated in colorectal cancer 4-6 , our results suggest that this is associated with inefficient de novo methylation. H3K27me3 is lost from these CGIs when they become aberrantly methylated 60 . 
